NasdaqGM:SUPNPharmaceuticals
Supernus Pharmaceuticals (SUPN) Is Up 8.9% After Q1 Beat And Reaffirmed 2026 Outlook Has The Bull Case Changed?
In early May 2026, Supernus Pharmaceuticals, Inc. reported first-quarter 2026 results showing revenue of US$207.71 million versus US$149.82 million a year earlier, with net loss narrowing to US$2.29 million from US$11.83 million.
On the same day, the company reiterated its full-year 2026 outlook, projecting total revenues of US$840 million–US$870 million and operating earnings of US$0–US$30 million, signalling management’s confidence in its current trajectory.
We’ll now examine how...